In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daewoong Pharmaceutical Co. Ltd.

www.daewoong.com

Latest From Daewoong Pharmaceutical Co. Ltd.

Can Daewoong’s P-CAB Unsettle Competition?

Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.

Research & Development Clinical Trials

Medytox, Daewoong’s Botox Strain Dispute Set To Simmer Until Commission Decision

The ongoing battle between Korea's Medytox and Daewoong Pharm over the source of the botulinum toxin strain in Daewoong’s product looks set to rumble on until a trade commission unveils the results of its probe next year.

South Korea Legal Issues

Korea Races For IPF Drug Development Amid Keen Global Interest

Following major global licensing out deals in the sector this year by South Korean bioventures Bridge Biotherapeutics and TiumBio, Scrip takes a look at why firms in the country are competitively pursuing development of drugs for IPF.

South Korea Respiratory

Suspicions Raised Over Medytox’s Botulinum Toxin Amid Ongoing Court Battle

Shares of Korea's Medytox fell on suspicions that it supplied botulinum toxin to local hospitals before the product's approval in 2006. The concerns add to other manufacturing issues that have been denied by the company, which pointed to a rival as the possible source amid an ongoing legal battle over the strain used in the product.

South Korea Aesthetics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Daewoong Pharmaceutical Co. Ltd.
  • Senior Management
  • Sengho Jeon, CEO
  • Contact Info
  • Daewoong Pharmaceutical Co. Ltd.
    Phone: (82) 2 550 8533
    Bongeunsa-ro114-gil 12
    Gangnam-gu
    Seoul, 135 715
    South Korea
UsernamePublicRestriction

Register